

Hammersmith Medicines Research  
Cumberland Avenue  
Park Royal  
London NW10 7EW

Telephone 020 8961 4130  
Facsimile 020 8961 8665  
E-mail [vparker@hmrlondon.com](mailto:vparker@hmrlondon.com)  
[www.hmrlondon.com](http://www.hmrlondon.com)

Dr Jan Downer  
Chairman, London – Harrow Research Ethics Committee

02 June 2015

Dear Dr Downer

**REC reference number 12/LO/1813:** Can netazepide eradicate the inflammatory response of the gastric mucosa to *H. pylori* infection?

Protocol number: T-019 HMR Code: 12-502

EudraCT number: 2012-002183-27


**Summary of trial report**

The committee approved this study on 24 December 2012. On 28 August 2014, we informed you that we'd temporarily halted the study while the sponsor investigated if a new compound would be more suitable than netazepide.

The sponsor has now started development of a new gastrin receptor antagonist. So, the study was terminated early on 01 April 2015. No subjects were recruited and no data were generated. Because of that, this letter is to inform you that the sponsor won't submit a summary of trial report for this study.

Please direct all correspondence to Victoria Parker, PA to the Chairman ([vparker@hmrlondon.com](mailto:vparker@hmrlondon.com)), and copy Jaya Varsani ([jvarsani@hmrlondon.com](mailto:jvarsani@hmrlondon.com)).

Kind regards



Malcolm Boyce  
Principal Investigator



Certificate no.GB99/50577

Healthmark

Hammersmith Medicines Research Limited  
Registered Office: Cumberland Avenue, London, NW10 7EW  
Registered in England No 2779946



National  
Training Awards  
2004